Corbus Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference
03/11/2022 - 08:05 AM
NORWOOD, Mass. , March 11, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today announcing that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022 at 8:00 AM ET .
In addition to the fireside chat, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
A live webcast of the fireside chat will be accessible on the Events page of the Investors section of the Corbus website, www.corbuspharma.com . The webcast replay will be available approximately two hours after the event and will be archived for 90 days.
About Corbus Corbus is an immunology company committed to connecting innovation to our purpose of improving lives by developing new medicines that target the nexus between the immune system and cancer. Corbus' current pipeline includes anti-integrin monoclonal antibodies that block activation of TGFβ and small molecules that activate or inhibit the endocannabinoid system. Corbus is headquartered in Norwood, Massachusetts . For more information on Corbus, visit corbuspharma.com . Connect with us on Twitter , LinkedIn and Facebook .
INVESTOR CONTACT: Brian Walsh , VP, Corporate Development Email: brian.walsh@corbuspharma.com Phone: +1 (781) 264 8944
View original content to download multimedia:https://www.prnewswire.com/news-releases/corbus-pharmaceuticals-to-present-at-the-oppenheimer-32nd-annual-healthcare-conference-301500516.html
SOURCE Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings Inc
CRBP Rankings
#601 Ranked by Stock Gains
CRBP Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Norwood
About CRBP
corbus pharmaceuticals holdings, inc. (nasdaq: crbp) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. the company's lead product candidate, resunab™, is a first-in-class, oral anti-inflammatory drug that acts to resolve inflammation through an endogenous pathway. resunab is scheduled to commence three phase 2 clinical trials in 2015 for the treatment of cystic fibrosis, diffuse systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation contributes to disease progression. resunab also has the potential to treat additional rare, inflammatory diseases.